The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women

Status Completed

Clinical Trial Summary

This is a prospective comparative randomized controlled trial investigating the effect of two GnRH agonist trigger protocols on the ongoing pregnancy rate in hyper-responder women undergoing assisted reproductive technology.

Clinical Trial Description

Follicle maturation triggering is the final differentiation process of an immature egg before fertilization, either in normal or stimulated ovarian cycles in assisted reproductive techniques. This step has traditionally been accomplished by the administration of human chorionic gonadotropin (hCG) trigger which mimics LH activity. However, hCG is a primary cause of severe ovarian hyperstimulation syndrome (OHSS) in women and appears to initiate the complex cascade that leads to the development of serious medical complications. Numerous strategies have been suggested to prevent OHSS; one of these is the administration of a gonadotropin releasing hormone (GnRH) agonist trigger instead of hCG. Despite a high safety profile, the GnRH agonist trigger of follicle maturation was found to be associated with a decreased probability of clinical and ongoing pregnancy rates and very high miscarriage rates. A profoundly deficient luteal phase is believed to be the cause of compromised reproductive outcome. Our personal clinical practice at the AUBMC Fertility Center seems to indicate that a novel GnRH agonist administration protocol is associated with a comparable reproductive performance to standard hCG trigger. In this study, we aim to validate the above clinical impression and assess associated parameters of success. Therefore, a prospective comparative randomized controlled trial will be performed in order to investigate the effect of three repeated doses of GnRH agonist trigger "Triptorelin" accompanied by intensive Luteal Support on the ongoing pregnancy outcome in women who are hyper-responders to ovarian stimulation when undergoing assisted reproductive technology. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03169166
Study type	Interventional
Source	American University of Beirut Medical Center
Contact
Status	Completed
Phase	Phase 4
Start date	March 1, 2017
Completion date	October 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03607409` - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting	`NCT02312076` - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles	Phase 4
Terminated	`NCT02161861` - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study	N/A
Completed	`NCT03287479` - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)	N/A
Terminated	`NCT03522350` - Randomized Trial Comparing EmbryoScope With EmbryoScope+.	N/A
Completed	`NCT04496284` - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen	N/A
Completed	`NCT03623659` - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts	N/A
Completed	`NCT03895099` - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors	Phase 3
Active, not recruiting	`NCT04142112` - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation	N/A
Completed	`NCT03152643` - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer	N/A
Recruiting	`NCT03683771` - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting	`NCT03161119` - Comparing Two Different Embryo Transfer Catheters	N/A
Completed	`NCT04108039` - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.	N/A
Completed	`NCT03678558` - Oocyte Vitrification Aided With Cytochalasin B	N/A
Completed	`NCT03678584` - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)	N/A
Completed	`NCT03678571` - Oocyte Vitrification Aided With Latrunculin A	N/A
Completed	`NCT03677492` - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)	N/A
Completed	`NCT03678818` - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)	N/A
Completed	`NCT03678597` - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)	N/A
Completed	`NCT03678610` - Handling Medium for ICSI With Ionomycin and Latrunculin A	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms